nctId,primary_outcome_title,primary_outcome_pvalues
NCT01064440,Number of Participants With Treatment-emergent Adverse Events Following Intramuscular Administration of 8 and 16 mg Engensis (VM202) or Placebo in Subjects With Critical Limb Ischemia.,
NCT02887859,"Number of Participants With Aneurysm Formation, Anastomotic Bleeding or Spontaneous Rupture, HAV Infection, HAV Removal, and Significant Inflammation at the HAV Implantation Site",
NCT03018366,Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry,
NCT02376010,Coronary Artery Calcium (Serial Calcium Scans),
NCT03689946,Change in Noncalcified Coronary Artery Plaque Volume (NCPV),
NCT00496834,Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug,
NCT05742841,Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30,
